Sign inJoin waitlistJoin the waitlist

Trish Millard

Fellowship Program Director · University of Virginia Medical Center

Credentials: · · · · ·

History

University of Virginia Medical Center Fellowship
Present
University of Virginia Medical Center Fellowship
Present
University of Virginia Medical Center
Present

Hematology and Medical Oncology
University of Virginia Medical Center
2015–2018
Internal Medicine
University of Virginia Medical Center
2012–2015
Penn State College of Medicine
2007–2011
Lafayette College in Easton, PA
2003–2007

Research

Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series
Cardio-Oncology · 2020 · 26 citations
Replacing a Swiss ball for an exercise bench causes variable changes in trunk muscle activity during upper limb strength exercises
Dynamic Medicine · 2005 · 24 citations
Doege-Potter syndrome presenting with hypoinsulinemic hypoglycemia in a patient with a malignant extrapleural solitary fibrous tumor: a case report
Case report · Journal of Medical Case Reports · 2013 · 22 citations

Patrick Dillon
7 papers
Shayna Showalter
7 papers
CB
Christiana Brenin
5 papers
Lena Turkheimer
4 papers · 4 as a resident
Anita Clayton
2 papers
JS
Jenna Schlefman
2 papers
Lee Ritterband
2 papers
Max Meneveau
2 papers · 2 as a resident
Ajay Dhakal
1 paper
Akriti Gupta
1 paper · 1 as a resident
Antonio Abbate
1 paper · 1 as a fellow
Carla Falkson
1 paper

Clinical trials

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Site PI · Recruiting · Phase 2
Eli Lilly and Company
2026–2029
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2034
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2023–2033
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Site PI · Recruiting · Phase 2
Oana Danciu
2022–2029